IL6 and COVID-19: The analysis conducted allowed us to identify specific structural features within molecules of the furosemide family that directly interact with key active sites involved in the progression of COVID-19, particularly regarding anti-inflammatory cytokine activity against IL-6 and TNF-α [13].